Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...

Less than a month after the company from which it split more than three years ago, bluebird bio, sold for less than $30 million, the Cambridge drugmaker is being acquired by its partner Bristol Myers ...

CEO and chairman of CytomX, Sean McCarthy, PhD, said: “We are thrilled that our scientific expertise has attracted Regeneron as our newest collaborator, and we look forward to working closely ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

CEO John Maraganore said: "As we transition Alnylam toward commercialisation in rare diseases, the prospect of collaborating with a scientific leader like Regeneron on innovative medicines for ...

"One of the approaches I used in my project was bridging western medicine and also traditional indigenous practices." ...